UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER
| Site name: | University of Michigan Comprehensive Cancer Center | Active Prostate Cancer Clinical Trials: | |
| Contact: | Clinical Trials Office - University of Michigan Comprehensive | That match your search: | No search performed |
| Phone: | 800-865-1125 | ||
| Site email: | Not Provided |
7
Active Prostate Cancer Clinical Trials at University of Michigan Comprehensive Cancer Center:
| TRIAL ID | TITLE | TRIAL PHASE |
|---|---|---|
| NCT00309985 | CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED] | Phase 3 |
| NCT01267266 | A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer | Phase 2 |
| NCT01026623 | Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration- Resistant Prostate Cancer (CRPC) | Phase 1/Phase 2 |
| NCT01120236 | A Randomized Phase II Study of Combined Androgen Deprivation Versus Combined Androgen Deprivation With IMC-A12 for Patients With New Hormone-Sensitive Metastatic Prostate Cancer | Phase 2 |
| NCT01260688 | A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer | Phase 2 |
| NCT01046916 | A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA) | Phase 2 |
| NCT01163084 | A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate | Phase 1/Phase 2 |